Chronic Myelogenous Leukemia: Pregnancy in the Era of Stopping Tyrosine Kinase Inhibitor Therapy
- 20 April 2018
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (12) , 1250-1256
Abstract
No abstract availableThis publication has 39 references indexed in Scilit:
- Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNetBlood, 2012
- A systematic review of the fetal safety of interferon alphaReproductive Toxicology, 2012
- Will Imatinib Compromise Reproductive Capacity?The Oncologist, 2011
- Effect of imatinib on the biochemical parameters of the reproductive function in male Swiss albino miceIndian Journal of Pharmacology, 2011
- European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poorBlood, 2008
- Adult reproductive functions after early postnatal inhibition by imatinib of the two receptor tyrosine kinases, c-kit and PDGFR, in the rat testisReproductive Toxicology, 2008
- The effects of imatinib on pregnancy outcomeBlood, 2008
- Gene expression profiling of early follicular development in primordial, primary, and secondary folliclesFertility and Sterility, 2006
- Teratogen‐induced limb defectsAmerican Journal of Medical Genetics, 2002
- Omphalocele and gastroschisis in Europe: A survey of 3 million births 1980–1990American Journal of Medical Genetics, 1995